Literature DB >> 30941448

Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation.

Matilde Monteiro-Soares1,2, Inês Ribeiro-Vaz1,3, Edward J Boyko4,5.   

Abstract

Entities:  

Keywords:  Adverse drug reactions; Canagliflozin; Diabetic foot; Lower extremity amputation; SGLT2

Mesh：

Substances：

Year:  2019        PMID： 30941448     DOI： 10.1007/s00125-019-4861-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  32 in total

1.  Resurgence of Diabetes-Related Nontraumatic Lower-Extremity Amputation in the Young and Middle-Aged Adult U.S. Population.

Authors:  Linda S Geiss; Yanfeng Li; Israel Hora; Ann Albright; Deborah Rolka; Edward W Gregg
Journal:  Diabetes Care       Date:  2018-11-08       Impact factor: 19.112

2.  Ertugliflozin for Type 2 Diabetes.

Authors: 
Journal:  JAMA       Date:  2018-06-19       Impact factor: 56.272

3.  Predictive Laboratory Findings of Lower Extremity Amputation in Diabetic Patients: Meta-analysis.

Authors:  Jong-Lim Kim; Jin Yong Shin; Si-Gyun Roh; Suk Choo Chang; Nae-Ho Lee
Journal:  Int J Low Extrem Wounds       Date:  2017-11-16       Impact factor: 2.057

4.  Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial.

Authors:  Silvio E Inzucchi; Hristo Iliev; Egon Pfarr; Bernard Zinman
Journal:  Diabetes Care       Date:  2017-11-13       Impact factor: 19.112

Review 5.  HbA1c and Lower Extremity Amputation Risk in Patients With Diabetes: A Meta-Analysis.

Authors:  Zhen-Yu Zhou; Ya-Ke Liu; Hong-Lin Chen; Hui-Lin Yang; Fan Liu
Journal:  Int J Low Extrem Wounds       Date:  2015-06-29       Impact factor: 2.057

6.  Magnesium Supplementation and the Effects on Wound Healing and Metabolic Status in Patients with Diabetic Foot Ulcer: a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Reza Razzaghi; Farangis Pidar; Mansooreh Momen-Heravi; Fereshteh Bahmani; Hossein Akbari; Zatollah Asemi
Journal:  Biol Trace Elem Res       Date:  2017-05-24       Impact factor: 3.738

7.  The effects of vitamin D supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial.

Authors:  Reza Razzaghi; Hamideh Pourbagheri; Mansooreh Momen-Heravi; Fereshteh Bahmani; Jafar Shadi; Zahra Soleimani; Zatollah Asemi
Journal:  J Diabetes Complications       Date:  2016-06-23       Impact factor: 2.852

8.  Effect of Intensive Glycemic Control on Risk of Lower Extremity Amputation.

Authors:  Matthew P Goldman; Christopher J Clark; Timothy E Craven; Ross P Davis; Timothy K Williams; Gabriela Velazquez-Ramirez; Justin B Hurie; Matthew S Edwards
Journal:  J Am Coll Surg       Date:  2018-10-16       Impact factor: 6.113

9.  Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.

Authors:  Bruce Neal; Vlado Perkovic; David R Matthews; Kenneth W Mahaffey; Greg Fulcher; Gary Meininger; Ngozi Erondu; Mehul Desai; Wayne Shaw; Frank Vercruysse; Jacqueline Yee; Hsiaowei Deng; Dick de Zeeuw
Journal:  Diabetes Obes Metab       Date:  2017-01-25       Impact factor: 6.577

10.  Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).

Authors:  Patrick B Ryan; John B Buse; Martijn J Schuemie; Frank DeFalco; Zhong Yuan; Paul E Stang; Jesse A Berlin; Norman Rosenthal
Journal:  Diabetes Obes Metab       Date:  2018-06-25       Impact factor: 6.577
View more
  1 in total

Review 1.  Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Richard O Day; Jerry R Greenfield
Journal:  Drug Saf       Date:  2020-10-23       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.